01.10.2001
Evaluation of HER2 status: For the treatment of metastatic breast cancers by humanized anti-HER2 monoclonal antibody (trastuzumab) (Pathological committee for optimal use of trastuzumab)
Erschienen in: Breast Cancer | Ausgabe 4/2001
Einloggen, um Zugang zu erhalten